Gapping up
In reaction to earnings/guidance:
- OSPN +25%, QUAD +20.4%, CHGG +17.5%, MTCH +15%, BAND +15%, YUMC +13.6%, HZNP +8%, SCI +7.9%, SMCI +6.9%, CZR +6.7%, CRUS +6.1%, BRX +5%, AMD +4.9%, AEIS +4.7%, XHR +4.7%, NVO +4.6%, ZETA +3.9%, FCPT +3.6%, INSP +3.5%, VRAY +3.4%, OI +3.3%, TRMB +3.3%, ALKS +3.2%, UTHR +3.1%, RITM +2.9%, INTU +2.8%, MDLZ +2.8%, ZBH +2.6%, CRK +2.5% (also reinstates dividend), MGY +2.5%, DIN +2.3%, WU +2.1%, CVS +2%, AYX +1.9%, GSK +1.9%, NMR +1.5%, PEAK +1.3%, SMG +1.3%, MIR +1%
Other news:
- BNFT +47.4% (VOYA to acquire BNFT)
- ARCT +31.9% (collaboration and license agreement with CSL Seqirus)
- EDAP +9.2% (Focal One HIFU reimbursement raised under CMS)
- TRQ +5.9% (RIO reaches agreement with certain shareholders of TRQ)
- DD +5.1% (DD terminates deal to acquire ROG)
- SPXC +5% (divests 3 subsidiaries that hold asbestos liabilities)
- LIAN +4.2% (first patient dosed in the Phase 3 LIBRA trial of TP-03)
- BMBL +3.9% (in sympathy with strong MTCH earnings)
- AROC +3.8% (announces successful completion of a field pilot of its methane capture technology)
- ABUS +3.3% (clinical data from two trials)
- EBS +3% (announced results from Phase 2 study evaluating its single dose chikungunya)
- PRGO +2.5% (announces $170 mln investment to expand US infant formula manufacturing)
Analyst comments:
- CRWD +0.5% (initiated with an Outperform at Macquarie)